Results 1 to 10 of about 1,330 (154)

Andexanet alfa for the reversal of anticoagulation: Dutch practice data [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Andexanet alfa is a reversal agent for factor Xa (FXa) inhibitors (rivaroxaban and apixaban) and is available for the treatment of severe FXa inhibitor-associated bleeding.
Jurjen F. Krommenhoek, Wendy Beekman, Flip Kor, Pim Gal, Willemijn E.M. Berkhout, Karina Meijer, Dionne C.W. Braeken, Frederikus A. Klok, Hugo ten Cate, Renske H. Olie   +9 more
doaj   +4 more sources

Combined Antithrombin and Heparin Supplementation to Blood for Restoring Heparin Responsiveness After Andexanet Alfa Exposure: An In Vitro Model [PDF]

eJHaem
Background: Andexanet alfa, a Gla‐domainless mutant factor Xa (GDXa), reverses oral FXa inhibitors but can cause severe heparin resistance during cardiopulmonary bypass (CPB).
Amir L. Butt, Hisako Okada, Kofi B. Vandyck, Nana Toyoda, Shinobu Itagaki, Kenneth E. Stewart, Kenichi A. Tanaka   +6 more
doaj   +3 more sources

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa

Clinical and Applied Thrombosis/Hemostasis, 2020
Andexanet alfa is a recombinant factor Xa decoy protein, designed to reverse bleeding associated with oral anti-Xa agents. Andexanet alfa is also reported to neutralize the effects of heparin-related drugs.
Debra Hoppensteadt, Fakiha Siddiqui, Eduardo Ramacciotti   +2 more
exaly   +2 more sources

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation

Therapeutic Advances in Drug Safety, 2019
Background: Review of clinical data on andexanet alfa for the reversal of factor Xa (FXa) inhibitor associated anticoagulation. Data sources: In the present review, we identified articles via PubMed using the combined keywords andexanet alfa, apixaban ...
Elise Carpenter, Eric Dietrich, Divita Singh   +2 more
exaly   +2 more sources

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding

Clinical and Applied Thrombosis/Hemostasis, 2021
The aim of this retrospective study was to compare andexanet alfa and 4-factor prothrombin complex (4F-PCC) for reversal of factor Xa (FXa)-inhibitor bleeding. Patients that received andexanet alfa for reversal were included.

exaly   +2 more sources

Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study

Western Journal of Emergency Medicine, 2023
Background: There are no randomized trials comparing andexanet alfa and 4 factor prothrombin complex concentrate (4F-PCC) for the treatment of factor Xa inhibitor (FXa-I)-associated bleeds, and observational studies lack important patient characteristics.
Adam J. Singer, Mauricio Concha, James Williams, Caitlin S. Brown, Rafael Fernandes, Henry C. Thode Jr., Marylin Kirchman, Alejandro A. Rabinstein   +7 more
doaj   +1 more source

Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding

Journal of the American College of Emergency Physicians Open, 2022
Objective Compare 30‐day mortality among patients receiving the specific reversal agent andexanet alfa versus replacement prothrombin complex concentrate (PCC) in the management of direct‐acting oral anticoagulant (DOAC)–related bleeds.
Alexander T. Cohen, Megan Lewis, Augusta Connor, Stuart J. Connolly, Patrick Yue, John Curnutte, Raza Alikhan, Peter MacCallum, Joachim Tan, Laura Green   +9 more
doaj   +1 more source

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

Clinical and Applied Thrombosis/Hemostasis, 2022
Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors.
Alex C. Spyropoulos MD, Bríain Ó Hartaigh PhD, Zhun Cao PhD, MA, Harjeet Caberwal PharmD, Craig Lipkin MS, Michaela Petrini PA-C, MHS, Cheng Wang MD, PhD   +6 more
doaj   +1 more source

Real-World Observational Review of Andexanet Alfa Prescribing and Utilization Outcomes at a Community Teaching Hospital

Critical Care Explorations, 2021
Objectives:. Andexanet alfa is the first approved antidote in the management of life-threatening bleeds in patients treated with Xa inhibitors. The ANNEXA-4 study was successful in reducing factor Xa levels during time of administration but lacked ...
Kristine A. Sobolewski, PharmD, BCPS, Alison Brophy, PharmD, BCPS, BCCCP, Seohyun (Claudia) Choi, PharmD, BCCCP, Yekaterina Opsha, PharmD, BCPS-AQ Cardiology, AACC, FHFSA   +3 more
doaj   +1 more source

Institutional Experience of Using Andexanet Alfa [PDF]

Cureus, 2020
Given their ease of use, safety, and efficacy, direct-acting oral anticoagulants (DOACs) are nowadays widely used in patients with atrial fibrillation or venous thromboembolism, with or without an association with malignancy. Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that reverses the inhibition of factor Xa ...
Khadka, Sushmita, Kasireddy, Vineela, Dhakal, Pravash   +2 more
openaire   +2 more sources